[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd ADR (RHHBY)

Roche Holding Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 333,816,192
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,471 M
  • Annual Income, $ 15,546 M
  • EBIT $ 0 M
  • EBITDA $ 26,387 M
  • 60-Month Beta 0.50
  • Price/Sales 4.36
  • Price/Cash Flow 14.54
  • Price/Book 7.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.97 (1.86%)
  • Most Recent Dividend 0.972 on 03/13/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.0600 +0.32%
on 06/01/26
53.5400 -6.20%
on 05/22/26
-0.7801 (-1.53%)
since 05/01/26
3-Month
47.0500 +6.74%
on 03/20/26
58.4300 -14.05%
on 03/02/26
-9.3301 (-15.67%)
since 02/27/26
52-Week
37.5100 +33.88%
on 08/11/25
60.8500 -17.47%
on 02/24/26
+9.9199 (+24.62%)
since 05/30/25

Most Recent Stories

More News
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight...

RHHBY : 50.2199 (-4.16%)
3G Capital Exits Microsoft Stock in Major Portfolio Shift. MSFT Is Still One of the Best AI Plays Now.

3G Capital dumped Microsoft stock and piled into semiconductor names. Here's what the move says about AI investing right now, and whether MSFT remains a buy.

MSFT : 460.52 (+2.28%)
BABA : 125.40 (+0.95%)
BAYRY : 10.1500 (-3.79%)
JNJ : 223.51 (-0.81%)
MBGAF : 60.1145 (-0.74%)
ACN : 196.59 (+5.09%)
RHHBY : 50.2199 (-4.16%)
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages ...

RHHBY : 50.2199 (-4.16%)
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

First approved ctDNA MRD-guided therapy reinforcing Genentech’s commitment to innovation and practice-changing precision medicine New treatment approach...

RHHBY : 50.2199 (-4.16%)
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

New real-world data confirm Vabysmo’s potent retinal drying in wet AMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease...

RHHBY : 50.2199 (-4.16%)
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

‘All Eyes on DME’ campaign aims to educate and empower people impacted by or at-risk for diabetic macular edema (DME)—a serious, common and often overlooked eye condition ...

RHHBY : 50.2199 (-4.16%)
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis...

RHHBY : 50.2199 (-4.16%)
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ...

RHHBY : 50.2199 (-4.16%)
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) ...

RHHBY : 50.2199 (-4.16%)
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...

RHHBY : 50.2199 (-4.16%)
CCCC : 4.38 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 52.3666
2nd Resistance Point 51.8733
1st Resistance Point 51.0466
Last Price 50.2199
1st Support Level 49.7266
2nd Support Level 49.2333
3rd Support Level 48.4066

See More

52-Week High 60.8500
Fibonacci 61.8% 51.9341
Last Price 50.2199
Fibonacci 50% 49.1800
Fibonacci 38.2% 46.4259
52-Week Low 37.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.